PharmaEssentia

6446.TW

18.59 USD

1.66

+9.81%

Overview

Last close

18.59 usd

Market cap

6.34B usd

52 week high

23.57 usd

52 week low

13.51 usd

Target price

20.3 usd

Valuation

P/E

45.2583

Forward P/E

N/A

Price/Sales

14.1808

Price/Book Value

6.5853

Enterprise Value

5.54B usd

EV/Revenue

12.6817

EV/EBITDA

41.3625

Key financials

Revenue TTM

437.05M usd

Gross Profit TTM

389.71M usd

EBITDA TTM

127.53M usd

Earnings per Share

0.41 usd

Dividend

0.03 usd

Total assets

1.13B usd

Net debt

-679.50M usd

About

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.